In a case of first impression, the New Jersey Appellate Division held in January 2020 that an employee’s costs to use medical marijuana to treat chronic pain resulting from a work place injury is reimbursable by his employer.

This case arose out of a construction accident in 2001. Vincent Hager was working on a construction site when a truck delivering concrete dumped its load on him. Following the accident, Hager immediately experienced lower back pain that radiated down both legs, which he described as a “shooting and stabbing pain.” Initially, Hager’s employer, M&K, denied Hager’s workers’ compensation claim. While the claim was pending, Hager began to treat his injuries/pain with marijuana, as made available by New Jersey’s Compassionate Use Medical Marijuana Act (MMA), and sued M&K for reimbursement.


Continue Reading

New Jersey is now among the first three states to have its Hemp Program approved by the United States Department of Agriculture (the “USDA”). The 2018 Farm Bill legalized industrial hemp production nationwide by removing hemp and its derivatives, such as CBD, from the definition of marijuana under the Controlled Substances Act (“CSA”) and by providing a detailed framework for the cultivation of hemp.

Continue Reading

In June 2019, the Legislature passed the New Jersey Hemp Farming Act (the “HFA”). This is great news for the “Garden State.” New Jersey has hundreds of thousands of acres in farmland and hemp cultivation may prove to be a lucrative business.

Previously, hemp cultivation in New Jersey was limited to non-germinating seeds and stalks

CBD products: you may have seen them at your local grocery store, convenience store, or chiropractor’s office in the form of gummies, brownies, sodas, and cookies. CBD is one of many cannabinoids found in the cannabis plant. Unlike THC, which gives users a “high,” CBD contains little to no psychoactive properties, but comes with many benefits. CBD is being heavily studied and is showing great promise as a nutritional and wellness supplement. CBD products are currently being used to treat pain, inflammation, stress, and symptoms resulting from a wide range of medical conditions, such as epilepsy, multiple sclerosis, arthritis, anxiety, and chronic pain. CBD binds to the body’s cannabinoid receptors to induce feelings of calmness and pain relief. It has been hailed as a safer, more natural alternative to opioids and other addictive drugs.

While the CBD craze has resulted in an influx of CBD products hitting the market, the CBD market remains unregulated and susceptible to abuse and deceptive practices. The Food and Drug Administration (FDA) seized various CBD products from store shelves across the country after health claims relating to products which are not approved by the FDA, but suggest they are approved and/or intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases like cancer and Alzheimer’s disease. After the passage of the Agricultural Improvement Act (the “Farm Bill”), which legalized the cultivation, processing, and sale of hemp and hemp products, the FDA Commissioner reaffirmed that CBD, regardless of whether or not it is derived from hemp, cannot be lawfully marketed with a claim of therapeutic benefit without prior FDA approval.


Continue Reading

This article was co-authored with Bojana Petkovic, Project Manager, at LoudCloudHealth.com

The trend of cannabis legalization is spreading throughout the globe. Uruguay and Canada became the first two countries to fully legalize the plant for both medicinal and recreational purposes. The USA has not yet done the same on a federal level, nevertheless some states have already passed laws that allow growing, processing, distributing, and using cannabis products.

In this article, we discuss the world of cannabis legalization, talk a little bit about the history involved as well as the public’s opinion, potential benefits and risks of cannabis use, and more.


Continue Reading

In December 2018, Congress approved the Agriculture Improvement Act of 2018 (the “Farm Bill”) which authorized the production of hemp and removed hemp and hemp seeds from the DEA’s schedule of illegal Controlled Substances. After passage of the Farm Bill, questions arose with respect to interstate hemp transportation and who could obtain a license to produce hemp. Adding to the confusion, a number of Midwestern states seized hemp traveling through their borders and charged drivers with felonies for interstate drug trafficking.

Continue Reading

After passage of the Agricultural Improvement Act of 2018 (“The Farm Bill”), many professionals in the cannabis industry wondered how the new law would affect the U.S. Patent and Trademark Office’s (USPTO) stance on trade and service marks for cannabis sativa L species (hemp) and hemp-related goods and services.

Continue Reading

On June 3rd, the New Jersey Department of Health (DOH) announced will be seeking applicants for 108 additional medical marijuana licenses across the state. License applications will be available online July 1st and must be submitted by August 15th.

The expansion of medical cannabis facilities intends to accommodate the 30,000 new patients now qualified for medical marijuana under Opioid Use Disorder, Tourette’s syndrome, migraine, anxiety, and chronic pain conditions. New Jersey now has more than 47,000 medical marijuana patients, an exponential increase from the 17,000 patients in 2018.


Continue Reading

Although New Jersey lawmakers cancelled a vote on an adult-use recreational cannabis bill recently, medical cannabis use gained some support following a ruling from the Appellate Division of the Superior Court of New Jersey that an employer’s failure to accommodate medical marijuana use by an employee constituted a valid basis for an employment discrimination claim.

Continue Reading

The Patent Trial and Appeal Board (PTAB) issued an opinion earlier this year lending support to those interested in seeking patents related to cannabis. GW Pharmaceuticals, a U.K. company focused on therapeutic cannabinoids, walked away with a partial win concerning a patent that involved the use of cannabinoids to treat epilepsy.

Continue Reading